Chiron Begins Fluvirin Manufacturing After U.K. Clears Site
This article was originally published in The Pink Sheet Daily
Executive Summary
The U.K. Medicines & Healthcare products Regulatory Agency lifts its suspension of Chiron's license to manufacture Fluvirin at its Liverpool facility. FDA says it will inspect the facility once "all the critical stages of manufacturing are in full swing."
You may also be interested in...
Chiron To Meet With U.K. Regulatory Authorities On Fluvirin Suspension
The company does not anticipate the three-month manufacturing suspension will be lifted following the Oct. 6 meeting. Chiron's projected 48 mil. doses of flu vaccine were expected to account for nearly 50% of the U.S. supply.
Chiron’s European Flu Vaccine Dose Expectations Cut By 8 Mil.
Only 4 mil. doses of Chiron's Begrivac flu vaccine are expected to be supplied to non-U.S. markets after quality assurance concerns at Chiron’s Marburg, Germany facility leads the company to reduce supply expectations. FDA is beginning to inspect Liverpool plant, where manufacturing problems limited Fluvirin supply for 2004/2005.
Chiron’s European Flu Vaccine Dose Expectations Cut By 8 Mil.
Only 4 mil. doses of Chiron's Begrivac flu vaccine are expected to be supplied to non-U.S. markets after quality assurance concerns at Chiron’s Marburg, Germany facility leads the company to reduce supply expectations. FDA is beginning to inspect Liverpool plant, where manufacturing problems limited Fluvirin supply for 2004/2005.